Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Patrizia Tosi, Michèle Cavo, Elena Zamagni et al.|PubMed|2002Cited by 111
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.Michèle Cavo, Michele Baccarani, Nicoletta Testoni et al.|Blood|2008Cited by 10
Salvage Therapy With Thalidomide In Patients With Advanced Relapsed/Refractory Multiple MyelomaP. Tosi, Michèle Cavo, Elena Zamagni et al.|Journal of the Peripheral Nervous System|2002Cited by 10
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Alessandro Re et al.|The Lancet Haematology|2025Cited by 6
<i>TP53</i>, <i>CD36</i> Mutations and <i>CDKN2A</i> Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 TrialRiccardo Moia, Carlo Visco, Maria Elena Carazzolo et al.|Blood|2024Cited by 3